<DOC>
	<DOCNO>NCT00805064</DOCNO>
	<brief_summary>The aim pilot study investigate effect intravitreal combination therapy use triamcinolone bevacizumab patient retinal vein occlusion ( RVO ) .</brief_summary>
	<brief_title>Combined Triple Procedure Retinal Vein Occlusion ( RVO )</brief_title>
	<detailed_description>This prospective study case series conduct 47 patient ( n = 47 eye ; f/m : 21/26 ; mean age : 66.6 year ) ischemic central RVO ( CRVO ) ( n = 15 ) , non-ischemic CRVO ( n = 7 ) , branch RVO ( BRVO ) ( n = 25 ) . A core par plana vitrectomy aspiration 1.5 ml vitreous infusion balance salt solution ( BSS ; 1 ml ) , 8 mg ( 0.4 ml ) triamcinolone , 1.25 mg ( 0.1 ml ) bevacizumab perform single sutureless sclerotomy 23 gauge probe tip . At baseline follow-up , best correct visual acuity ( BCVA ; 6 Snellen ) , intraocular pressure ( IOP ; Goldmann tonometry ) , central macular thickness ( optical coherence tomography ) determine . In addition , need treatment adverse event monitor .</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>Ischemic central RVO ( CRVO ) Nonischemic CRVO Branch RVO ( BRVO ) Visual deterioration due acute chronic inflammation Post trauma Macular edema origin Intravitreal drug treatment within last 4 month</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>